Pro­teosta­sis shares whacked hard as CF drug falls short; Ad­vax­is ax­es tri­al plans in wake of a clin­i­cal hold

→ Pro­teosta­sis tried mighty hard to per­suade in­vestors that its pos­i­tive bio­mark­er da­ta from a study of its cys­tic fi­bro­sis drug PTI-801 un­der­scored the drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER